What trade-off was the committee considering between net clinical effects and costs?
The committee was considering the potential cost savings from a reduced number of all cause hospitalisations for those treated with MRAs against the potential cost of acute kidney injury (AKI) events occurring in those treated with MRAs. The committee agreed that the high cost of AKI would likely outweigh any potential cost savings from reduced hospitalisation.